ClinicalTrials.gov
ClinicalTrials.gov Menu

An Observational Study of Lung Cancer Related Symptoms and Disease Control Rate in Patients With Non-Small Cell Lung Cancer Receiving First-Line Platinum-Based Chemotherapy With or Without Avastin (Bevacizumab)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01358942
Recruitment Status : Completed
First Posted : May 24, 2011
Last Update Posted : November 2, 2016
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This prospective observational study will evaluate the evolution of lung cancer related symptoms and their correlation with the disease control rate (complete response, partial response and stable disease) in patients with non-small cell lung cancer initiating first-line treatment with standard platinum-based chemotherapy with or without Avastin (bevacizumab). Data will be collected from each patient at baseline and after 4-6 cycles of chemotherapy.

Condition or disease
Non-Squamous Non-Small Cell Lung Cancer

Study Type : Observational
Actual Enrollment : 156 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Observational, Epidemiological and Non Interventional Study Evaluating the Evolution of Lung Cancer Related Symptoms and Its Correlation With Disease Control Rate in Patients With Non-Small Cell Lung Cancer (NSCLC) Initiating First-line Treatment With Platinum Based Standard Chemotherapy.
Study Start Date : May 2011
Actual Primary Completion Date : November 2012
Actual Study Completion Date : November 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Group/Cohort
Cohort



Primary Outcome Measures :
  1. Change in lung cancer related symptoms (LCSS questionnaire) [ Time Frame: up to approximately 6 months (4-6 cycles of chemotherapy) ]
  2. Correlation of lung cancer related symptoms and disease control rate (complete response, partial response, stable disease according to RECIST criteria) [ Time Frame: approximately 2 years ]

Secondary Outcome Measures :
  1. Frequency/severity of lung cancer related symptoms (LCSS questionnaire) [ Time Frame: approximately 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Non-small cell lung cancer patients initiating treatment with platinum-based chemotherapy +/- bevacizumab
Criteria

Inclusion Criteria:

  • Adult patients, >/= 18 years of age
  • Histologically or cytologically confirmed non-small cell lung cancer
  • Initiating first-line treatment with standard platinum-based chemotherapy, with or without bevacizumab

Exclusion Criteria:

  • Contraindications to the use of platinum-based chemotherapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01358942


Locations
Spain
Vitoria, Alava, Spain, 01009
Alcoy, Alicante, Spain, 03804
Elche, Alicante, Spain, 03203
Elda, Alicante, Spain, 03600
Oviedo, Asturias, Spain, 33011
Jerez de La Frontera, Cadiz, Spain, 11407
San Sebastian, Guipuzcoa, Spain, 20080
Mahon, Islas Baleares, Spain, 07703
Palma de Mallorca, Islas Baleares, Spain, 07012
Palma de Mallorca, Islas Baleares, Spain, 07014
Logroño, La Rioja, Spain, 26006
Alcala de Henares, Madrid, Spain, 28805
Melilla, Malaga, Spain, 52005
Pamplona, Navarra, Spain, 31006
Pamplona, Navarra, Spain, 31008
Tudela, Navarra, Spain, 46010
Sagunto, Valencia, Spain, 46520
Xativa, Valencia, Spain, 46800
Bilbao, Vizcaya, Spain, 48013
Alicante, Spain, 3010
Barcelona, Spain, 08006
Barcelona, Spain, 08017
Barcelona, Spain, 08906
Castellon, Spain, 12002
Jaen, Spain, 23007
Madrid, Spain, 28031
Madrid, Spain, 28033
Madrid, Spain, 28040
Madrid, Spain, 28041
Madrid, Spain, 28046
Madrid, Spain, 28050
Malaga, Spain, 29010
Navarra, Spain, 31008
Pontevedra, Spain, 36002
Segovia, Spain, 40002
Valencia, Spain, 46015
Valencia, Spain, 46017
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01358942     History of Changes
Other Study ID Numbers: ML25493
First Posted: May 24, 2011    Key Record Dates
Last Update Posted: November 2, 2016
Last Verified: November 2016

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms